Hormone replacement therapy for women at risk of Alzheimer’s
2023
Norwich Medical School, Norwich, United Kingdom
The risk of dementia is higher in women than men. The metabolic consequences of estrogen decline during menopause accelerate neuropathology in women. Here, the researchers investigate the modulating role of APOE genotype and age at hormone replacement therapy (HRT) initiation on the heterogeneity in cognitive response to HRT. The analysis used baseline data from 1906 participants in the European Prevention of Alzheimer’s Dementia (EPAD) cohort. Multiple linear regression models were used to examine the impact of age of HRT initiation according to APOE4 carrier status on various cognitive and MRI outcomes. HRT introduction is associated with improved delayed memory in APOE4 carriers only. This may represent an effective targeted strategy to mitigate the higher lifetime risk of Alzheimer’s in this large at-risk population subgroup.
Hormone replacement therapy is associated with improved cognition and larger brain volumes in at-risk APOE4 women: results from the European Prevention of Alzheimer’s Disease (EPAD) cohort
Rasha N. M. Saleh
Added on: 01-19-2023
[1] https://alzres.biomedcentral.com/articles/10.1186/s13195-022-01121-5[2] https://neurosciencenews.com/hrt-genetics-alzheimers-22257/
